Increased Levels of Tumor Necrosis Factor–α Involved in Rituximab-Related Acute Pulmonary Fibrosis in Diffuse Large B-Cell Lymphoma | Zendy

Xueya Zhang | Zendy; XiZhe Guo | Zendy; Jingxin Pan | Zendy

Open Access

Increased Levels of Tumor Necrosis Factor–α Involved in Rituximab-Related Acute Pulmonary Fibrosis in Diffuse Large B-Cell Lymphoma

Author(s) -

Xueya Zhang,

XiZhe Guo,

Jingxin Pan

Publication year - 2015

Publication title -

american journal of clinical pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.859

H-Index - 128

eISSN - 1943-7722

pISSN - 0002-9173

DOI - 10.1309/ajcpaff3rl0sabej

Subject(s) - rituximab , medicine , chills , cd20 , pulmonary fibrosis , lymphoma , diffuse large b cell lymphoma , methylprednisolone , gastroenterology , fibrosis , pathology , tumor necrosis factor alpha , immunology

Rituximab is a chimeric anti-CD20 monoclonal antibody with murine variable regions and human IgG1 constant regions that depletes B lymphocytes. It is used with increasing frequency in the treatment of patients with other hematologic malignancies and nonhematologic diseases for its safety and efficacy. Its major adverse effects are infusion related and most commonly consist of fever, chills, dyspnea, and hypotension. Rituximab-induced lung injury, such as interstitial pneumonitis and pulmonary fibrosis, is a rare complication but has been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research